2023
Impact of Marital Stress on 1‐Year Health Outcomes Among Young Adults With Acute Myocardial Infarction
Zhu C, Dreyer R, Li F, Spatz E, Caraballo‐Cordovez C, Mahajan S, Raparelli V, Leifheit E, Lu Y, Krumholz H, Spertus J, D'Onofrio G, Pilote L, Lichtman J. Impact of Marital Stress on 1‐Year Health Outcomes Among Young Adults With Acute Myocardial Infarction. Journal Of The American Heart Association 2023, 12: e030031. PMID: 37589125, PMCID: PMC10547344, DOI: 10.1161/jaha.123.030031.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionCardiac-specific qualityGeneric health statusMyocardial infarctionBaseline healthMarital stressHealth outcomesHealth statusWorse patient-reported outcomesMental healthYoung adultsObservational cohort studyPatient-reported outcomesSocioeconomic factorsWorse mental healthReadmission 1Cause readmissionCohort studyYounger patientsRoutine screeningDepressive symptomsGreater oddsAnginaMale participantsOutcomes
2019
Population Impact of Generic Valsartan Recall
Jackevicius CA, Krumholz HM, Chong A, Koh M, Ozaki AF, Austin PC, Udell JA, Ko DT. Population Impact of Generic Valsartan Recall. Circulation 2019, 141: 411-413. PMID: 31707798, DOI: 10.1161/circulationaha.119.044494.Peer-Reviewed Original ResearchConceptsNational Ambulatory Care Reporting System databaseEmergency department visitsRegistered Persons DatabaseOntario Registered Persons DatabaseReporting System databaseHealth care systemDrug recallsSegmented regression analysisBaseline comorbiditiesOral medicationsDepartment visitsHospital admissionMedication useClinical outcomesDischarge diagnosisVital statusChronic conditionsHealthcare databasesHealth CanadaCare systemCanadian InstituteHealth informationPopulation impactPatientsRegression analysis
2018
Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome
Ko DT, Krumholz HM, Tu JV, Austin PC, Stukel TA, Koh M, Chong A, de Melo JF, Jackevicius CA. Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome. Circulation Cardiovascular Quality And Outcomes 2018, 11: e004194. PMID: 29535091, DOI: 10.1161/circoutcomes.117.004194.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overClopidogrelCost SavingsCost-Benefit AnalysisDatabases, FactualDrug CostsDrug SubstitutionDrugs, GenericFemaleHemorrhageHumansMaleOntarioPatient AdmissionPatient ReadmissionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRecurrenceRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsAcute coronary syndromeGeneric clopidogrelClinical outcomesCoronary syndromePrimary outcomeRecurrent acute coronary syndromeSubstantial healthcare cost savingsPopulation-based observational studyPropensity-weighted cohortsComposite of deathTransient ischemic attackComposite end pointEffect of clopidogrelElevation myocardial infarctionHealthcare cost savingsCox proportional hazardsRate of deathIschemic attackACS hospitalizationCause readmissionBaseline characteristicsHospital dischargeRecurrent hospitalizationsMean ageMyocardial infarction
2016
Access to Evidence-Based Statins in Low-Cost Generic Drug Programs
Jackevicius CA, Choi K, Krumholz HM. Access to Evidence-Based Statins in Low-Cost Generic Drug Programs. Circulation Cardiovascular Quality And Outcomes 2016, 9: 785-787. PMID: 27803089, DOI: 10.1161/circoutcomes.116.002985.Peer-Reviewed Original ResearchComparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome
Jackevicius CA, Tu JV, Krumholz HM, Austin PC, Ross JS, Stukel TA, Koh M, Chong A, Ko DT. Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome. Journal Of The American Heart Association 2016, 5: e003350. PMID: 27098970, PMCID: PMC4859299, DOI: 10.1161/jaha.116.003350.Peer-Reviewed Original ResearchConceptsGeneric atorvastatinACS hospitalizationSecondary outcomesClinical effectivenessAcute coronary syndrome hospitalizationPopulation-based cohort studyNew-onset diabetesAcute coronary syndromeDays of dischargePrespecified subgroup analysisPropensity-matched pairsInfrequent side effectsBrand-name medicationsSignificant differencesHealth care plansRecurrent ACSAdmission diagnosisAtorvastatin doseCardiovascular outcomesCoronary syndromeCohort studyRenal failureHeart failurePrimary outcomeMean age
2013
The Case for Generic Statins: Not If They Don’t Work So Well—Reply
Green JB, Ross JS, Krumholz HM. The Case for Generic Statins: Not If They Don’t Work So Well—Reply. JAMA Internal Medicine 2013, 173: 1474-1474. PMID: 23939523, DOI: 10.1001/jamainternmed.2013.7781.Commentaries, Editorials and LettersWhen Choosing Statin Therapy: The Case for Generics
Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.Commentaries, Editorials and Letters
2012
Statins: Is It Safe and Effective to Use Generic “Equivalents”?
Jackevicius CA, Tu JV, Krumholz HM. Statins: Is It Safe and Effective to Use Generic “Equivalents”? Canadian Journal Of Cardiology 2012, 29: 408-410. PMID: 23062664, DOI: 10.1016/j.cjca.2012.08.012.Peer-Reviewed Original ResearchAvoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise
Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise. JAMA Internal Medicine 2012, 172: 724-730. PMID: 22493409, PMCID: PMC3636774, DOI: 10.1001/archinternmed.2012.187.Commentaries, Editorials and Letters
2011
Generic Atorvastatin and Health Care Costs
Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic Atorvastatin and Health Care Costs. New England Journal Of Medicine 2011, 366: 201-204. PMID: 22149736, PMCID: PMC3319770, DOI: 10.1056/nejmp1113112.Peer-Reviewed Original ResearchACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution A Report of the American College of Cardiology Foundation Clinical Quality Committee
Holmes D, Becker J, Granger C, Limacher M, Page R, Sila C, Drozda J, Cacchione J, Erb B, Harrington R, Kennett J, Krumholz H, Masoudi F, Peterson E, Poppas A, Sahn D, Sanz M, Shahian D, Windle J, Wyman J. ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution A Report of the American College of Cardiology Foundation Clinical Quality Committee. Journal Of The American College Of Cardiology 2011, 58: 1287-1307. PMID: 21849242, DOI: 10.1016/j.jacc.2011.06.001.Peer-Reviewed Original ResearchUse of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials